Shigella is a leading cause of diarrheal disease worldwide. Shigella vaccines aim to help prevent the spread of the bacterial infection shigellosis, which is transmitted through contaminated food or water or direct person-to-person contact. There are currently no vaccines licensed for shigellosis prevention, but several candidates are being evaluated for safety and efficacy.

The Shigella Vaccines Market is estimated to be valued at US$ 574.20 million in 2023 and is expected to exhibit a CAGR of 6.4% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:
Increasing awareness about preventive medicines and growing research & development activities to develop an effective shigella vaccine are some key factors fueling growth of the shigella vaccines market. Various pharmaceutical companies and research institutions are conducting clinical trials to test candidates against prevalent Shigella strains. For instance, in 2020, the Drugs for Neglected Diseases initiative started a Phase III clinical trial of its experimental Shigella conjugate vaccine SgCb in Africa. The vaccine demonstrated high efficacy and tolerability in earlier studies. Positive results from such ongoing large-scale late-phase studies will help introduce a licensed vaccine in the market in the coming years.

Porter’s Analysis
Threat of new entrants: The threat of new entrants is moderately low as the Shigella vaccines market requires huge R&D investments and regulatory approvals. Establishing manufacturing facilities also requires large capital investments.
Bargaining power of buyers: The bargaining power of buyers is moderate. The demand for Shigella vaccines is increasing due to the growing prevalence of Shigella infections globally. However, the availability of alternative treatment options provides some bargaining power to buyers.
Bargaining power of suppliers: The bargaining power of suppliers is moderate to high. Key raw material suppliers enjoy economies of scale due to the specialized nature of inputs. This gives them control over pricing.
Threat of new substitutes: The threat of new substitutes is moderate as there are no highly effective substitutes available for vaccines. However, alternatives like antibiotics are used for treatment.
Competitive rivalry: High as major players compete on pricing and developing new formulations.

SWOT Analysis
Strengths: Growing research focus on developing improved Shigella vaccines. Increasing government support for immunization programs.
Weaknesses: High R&D costs involved. Requirement of multiple doses. Complex nature of the disease makes vaccine development challenging.
Opportunities: Rising Shigella infections globally. Expanding into developing markets. Co-developing multivalent combination vaccines.
Threats: Stringent regulatory approvals. Threat from alternatives like antibiotics. Reimbursement issues in certain countries.

Key Takeaways
The global Shigella vaccines market is expected to witness high growth, exhibiting CAGR of 6.4% over the forecast period, due to increasing burden of Shigella infections worldwide. Asia Pacific region dominates the global market due to high disease prevalence in densely populated countries like India and China. The Shigella vaccines market in North America is expected exhibit growth owing to expanding immunization programs in the region.

Regional analysis: Asia Pacific dominates the global Shigella vaccines market and is estimated to grow at the fastest rate during the forecast period. The high disease prevalence in densely populated countries like India and China drives the regional market.Government support for immunization programs will also aid market growth.

Key players: Key players operating in the Shigella vaccines market are MSD Wellcome Trust Hilleman Laboratories Pvt. Ltd., Novartis (Novartis Vaccines Institute for Global Health), and GlaxoSmithKline plc. Major players are focusing on new product approvals and geographical expansions to strengthen their market position.